Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Recent cuts to federal grants are set to have a widespread impact across numerous scientific and medical studies.

The Democratic Progressive Party (DPP) is appealing to the public for support on the government budget issue with eight ...

China's counter-espionage authority says it has identified four members of Taiwan's cyber warfare force. It claims the force ...

He argued that spending cuts and fund redistribution violated the government’s pact with the public. The DPP’s budget ...

The management of Whiteplains British School, Abuja, has written to Lateef Fagbemi, asking for an investigation into the ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

A sitting of Dublin District Coroner’s Court on Wednesday heard that nobody will face criminal proceedings for the double ...